Every 10-Q that Lifeward Ltd. (LFWD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LFWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFWD filings page.
Lifeward Ltd. reported second-quarter 2026 revenue of $6.6 million, up modestly from $5.7 million a year earlier, with six-month revenue essentially flat at $10.5 million versus $10.8 million in 2025. Gross profit for the first half was $4.1 million, down from $4.6 million.
The company posted a six‑month net loss of $22.3 million, nearly double the prior-year loss of $11.4 million, driven largely by $7.8 million in net financial expense from warrant and derivative liabilities and interest on new convertible notes. Operating cash outflow was $9.7 million. Management states that recurring losses, negative cash flows and limited liquidity raise substantial doubt about Lifeward’s ability to continue as a going concern without additional financing.
During the period, Lifeward closed the Oratech asset acquisition, allocating $4.9 million to in‑process R&D (expensed immediately) and $6.5 million to acquired cash, and completed the Skelable technology acquisition. It also issued $10 million of senior secured convertible notes with attached warrants and, in a July closing, added $5.6 million more in senior secured convertible notes, while reclassifying certain warrant and derivative liabilities to equity.
Lifeward Ltd. reported a sharply wider quarterly loss while closing a major strategic transaction and related financing. For the three months ended March 31, 2026, revenue was $3.9 million, down from $5.0 million, mainly from lower AlterG Anti-Gravity system shipments, and gross margin fell to 34.2% from 42.2%. Net loss increased to $10.8 million, driven largely by a one-time $4.9 million acquired in‑process R&D charge from the Oratech asset acquisition and higher interest expense on new convertible notes. On March 25, 2026, Lifeward acquired Oratech for total consideration of about $12.4 million and issued $10.0 million of secured convertible notes and related warrants to Oramed and Creative Value Capital at a $5.40 per share conversion price. Cash and cash equivalents rose to $11.4 million after the Oratech cash acquired and note financing, but the company disclosed an accumulated deficit of $295.5 million and concluded that “substantial doubt” exists about its ability to continue as a going concern without additional capital.
Lifeward Ltd. reported lower revenues and widening losses in the quarter ended June 30, 2025. Quarterly revenue was $5.7 million versus $6.7 million a year earlier, and six‑month revenue totaled $10.8 million versus $12.0 million. The company recorded a quarterly operating loss of $6.6 million and a six‑month net loss of $11.4 million. Cash and cash equivalents were $5.1 million at June 30, 2025 and total cash, cash equivalents and restricted cash were $5.5 million, with management estimating runway into the fourth quarter of 2025, raising substantial doubt about going concern.
The company recorded a $2.8 million goodwill impairment in Q2 2025 and eliminated an earnout liability. Lifeward completed multiple 2025 equity financings, including a January registered direct offering and a June public offering (4.0 million shares with warrants), and raised proceeds under an ATM program (964,118 shares sold for net proceeds of about $1.0 million). A favorable Administrative Law Judge ruling and CMS actions have established a Medicare pathway for ReWalk (HCPCS code K1007) with a lump‑sum purchase payment of $91,032, a material reimbursement development for the ReWalk product line.